casirivimab and imdevimab drug combination

a mixture of anti-SARS-Cov-2 antibodies

Also Known As:

REGEN-COV; REGN-COV; REGN-COV-2; REGN-COV2; REGN10987 and REGN10933 mixture; Ronapreve; Ronpreve; casirivimab and imdevimab; casirivimab plus imdevimab; casirivimab, imdevimab drug combination; casirivimab-imdevimab

Networked: 200 relevant articles (24 outcomes, 44 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Weinreich, David M: 11 articles (10/2022 - 01/2021)
2.	Yancopoulos, George D: 11 articles (10/2022 - 11/2020)
3.	Baum, Alina: 9 articles (10/2022 - 11/2020)
4.	Braunstein, Ned: 9 articles (10/2022 - 01/2021)
5.	Hamilton, Jennifer D: 9 articles (10/2022 - 01/2021)
6.	Hooper, Andrea T: 9 articles (10/2022 - 01/2021)
7.	Kyratsous, Christos A: 9 articles (10/2022 - 11/2020)
8.	Stahl, Neil: 9 articles (10/2022 - 11/2020)
9.	Mahmood, Adnan: 8 articles (10/2022 - 01/2021)
10.	Musser, Bret J: 8 articles (10/2022 - 01/2021)

Related Diseases

1.	COVID-19 05/01/2022 - "CONCLUSIONS: This economic analysis found that casirivimab/imdevimab is a cost-effective treatment for most ambulatory patients with COVID-19. " 01/01/2022 - "In conclusion, REGEN-COV was effective in reducing the risk of severe sequelae in high-risk COVID-19 patients." 01/01/2022 - "In this retrospective analysis of immunodeficient patients granted REGEN-COV under emergency compassionate use, REGEN-COV treatment was associated with rapid viral clearance and clinical improvement in patients with longstanding COVID-19. " 07/01/2022 - "REGN-CoV2 treatment was effective in patients with mild COVID-19 and could shorten the period of infectious viral shedding. " 05/01/2022 - "METHODS: A cost-effectiveness model was constructed to simulate the natural history of COVID-19 in ambulatory patients and to identify those patients for whom casirivimab/imdevimab may be a cost-effective treatment from a US payer perspective. "
2.	Infections 04/01/2022 - "From the 30 patients who presented with mild-to-moderate infection, 28 received casirivimab-imdevimab. " 01/01/2022 - "Subjects were stratified be REGEN-COV receipt within 72h of test positivity and by time period of infection. " 01/01/2022 - "Doubtful clinical benefit of casirivimab-imdevimab treatment for disease severity outcome of high-risk patients with SARS-CoV-2 delta variant infection." 06/17/2021 - "REGEN-COV also prevented overall infections, either symptomatic or asymptomatic (66.4% risk reduction). " 07/27/2022 - "We conducted a retrospective observational study of casirivimab/imdevimab recipients with mild-to-moderate COVID-19 infection in an emergency department or outpatient infusion center (July 1-August 20, 2021). "
3.	Disease Progression 07/01/2022 - "This study aimed to elucidate the risk factors for disease progression after casirivimab and imdevimab administration. " 07/01/2022 - "Casirivimab and imdevimab are effective in preventing hospitalization in outpatients with coronavirus disease 2019 (COVID-19); however, disease progression after casirivimab and imdevimab administration has been reported. " 02/01/2022 - " Our study demonstrated that patients with COVID-19 had similar disease progression rates regardless of casirivimab/imdevimab administration." 01/24/2023 - "To evaluate the success of a clinic for subcutaneous administration of casirivmab and imdevimab (REGEN-COV; Regeneron) for treatment of patients with symptomatic mild to moderate coronavirus disease 2019 (COVID-19) in terms of preventing disease progression and healthcare utilization. " 04/01/2023 - "Recently, monoclonal antibody combinations bamlanivimab/etesevimab and casirivimab/imdevimab received emergency use authorizations for use in non-hospitalized patients with mild-to-moderate COVID-19 at high risk of disease progression. "
4.	Neoplasms (Cancer) 09/04/2023 - "Conclusion Patients with cancer treated with REGEN-COV experienced a decreased risk for hospitalization, hospitalization duration, and total COVID-19-related costs. " 09/04/2023 - "In the main study, patients with COVID-19 with cancer were divided into two groups: those with and without REGEN-COV treatment. " 05/01/2022 - "REGEN-COV antibody combination in patients with lymphoproliferative malignancies and SARS-CoV-2 infection." 01/01/2022 - "We constructed multivariable logistic regression models to assess the differential association of REGEN-COV receipt with hospitalization within 30 days (primary outcome) and ED presentation; all models included three exposure terms (REGEN-COV receipt, Omicron vs Delta period, interaction of REGEN-COV with time period) and potential confounders (vaccination status, vaccine boosting, cancer diagnosis). " 11/01/2022 - "Though there have not been any reported cases of casirivimab/imdevimab causing myopericarditis, adverse cardiac events after monoclonal therapy have been reported mainly in cancer patients receiving monoclonal infusions."
5.	Fever (Fevers) 01/01/2023 - "As he had a high-grade fever and dry cough, and because his SpO2 level had dropped below 95% in the supine position, he was considered as being at a high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); therefore, he received combined REGN-COV2 antibody therapy. " 01/01/2023 - "He was treated with a combination of remdesivir (antiviral) and casirivimab/imdevimab (combination monoclonal antibodies) with immediate improvement in fever, respiratory symptoms, and neurologic symptoms."

Related Drugs and Biologics

1.	casirivimab and imdevimab drug combination
2.	Monoclonal Antibodies
3.	remdesivir
4.	Combined Antibody Therapeutics
5.	bamlanivimab and etesevimab drug combination
6.	Oxygen (Dioxygen)
7.	favipiravir
8.	Vaccines
9.	Antiviral Agents (Antivirals)
10.	2019-nCoV Vaccine mRNA-1273

Related Therapies and Procedures

1.	Therapeutics
2.	Artificial Respiration (Mechanical Ventilation)
3.	Aftercare (After-Treatment)
4.	Plasma Exchange
5.	Immunotherapy